Alphatec Holdings, Inc. (ATEC)
NASDAQ: ATEC · IEX Real-Time Price · USD
13.21
+0.24 (1.85%)
At close: May 2, 2024, 4:00 PM
13.25
+0.04 (0.30%)
After-hours: May 2, 2024, 5:51 PM EDT
Alphatec Holdings Revenue
In the year 2023, Alphatec Holdings had annual revenue of $482.26M with 37.45% growth. Revenue in the quarter ending December 31, 2023 was $137.97M with 30.23% year-over-year growth.
Revenue (ttm)
$482.26M
Revenue Growth
+37.45%
P/S Ratio
3.83
Revenue / Employee
$574,806
Employees
839
Market Cap
1.85B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.26M | 131.40M | 37.45% |
Dec 31, 2022 | 350.87M | 107.66M | 44.26% |
Dec 31, 2021 | 243.21M | 98.35M | 67.89% |
Dec 31, 2020 | 144.86M | 31.43M | 27.71% |
Dec 31, 2019 | 113.43M | 21.73M | 23.70% |
Dec 31, 2018 | 91.69M | -10.05M | -9.87% |
Dec 31, 2017 | 101.74M | -18.51M | -15.39% |
Dec 31, 2016 | 120.25M | -14.14M | -10.52% |
Dec 31, 2015 | 134.39M | -20.24M | -13.09% |
Dec 31, 2014 | 154.63M | -50.10M | -24.47% |
Dec 31, 2013 | 204.72M | 8.45M | 4.30% |
Dec 31, 2012 | 196.28M | -1.43M | -0.72% |
Dec 31, 2011 | 197.71M | 26.10M | 15.21% |
Dec 31, 2010 | 171.61M | 50.99M | 42.28% |
Dec 31, 2009 | 120.62M | 28.44M | 30.85% |
Dec 31, 2008 | 92.18M | 12.15M | 15.18% |
Dec 31, 2007 | 80.03M | 6.03M | 8.14% |
Dec 31, 2006 | 74.01M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Myriad Genetics | 753.20M |
Supernus Pharmaceuticals | 607.52M |
Harmony Biosciences Holdings | 582.02M |
UFP Technologies | 400.07M |
Catalyst Pharmaceuticals | 398.20M |
Beam Therapeutics | 377.71M |
Schrödinger | 216.67M |
Avadel Pharmaceuticals | 27.96M |
ATEC News
- 11 hours ago - ATEC to Present at Upcoming Conferences - Business Wire
- 15 days ago - ATEC to Report First Quarter Financial Results on May 7, 2024 - Business Wire
- 4 weeks ago - Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales - Business Wire
- 2 months ago - ATEC Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Highlights - Business Wire
- 3 months ago - ATEC to Present at Upcoming Conferences - Business Wire
- 4 months ago - ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance - Business Wire
- 4 months ago - ATEC to Present at the 2024 J.P. Morgan Healthcare Conference - Business Wire
- 6 months ago - ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance - Business Wire